SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (12123)1/17/2019 10:09:07 AM
From: tuck  Read Replies (1) | Respond to of 12215
 
What's interesting to me, is why they aren't chasing obesity this time around. Maybe that would require too high a dose and cause the safety issue to rear its ugly head again?

Cheers, Tuck



To: scaram(o)uche who wrote (12123)1/17/2019 10:10:06 AM
From: atticus4paws  Respond to of 12215
 
Exactly. I'm guessing that they forgot the word "absolute." I'll shoot 'em an email.



To: scaram(o)uche who wrote (12123)1/17/2019 10:36:34 AM
From: atticus4paws  Read Replies (1) | Respond to of 12215
 
My other question would be how long until the VTE's showed up in the prior generation drug, given the earlier trials were 26 weeks. Anyway, still a long way from the finish line.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News